Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR)’s stock price hit a new 52-week low during mid-day trading on Tuesday. The company traded as low as C$13.37 and last traded at C$13.27, with a volume of 10,398 shares traded. The stock had previously closed at C$13.40.
Cipher Pharmaceuticals Trading Up 0.3%
The business has a fifty day moving average price of C$13.70 and a 200-day moving average price of C$15.71. The company has a quick ratio of 2.67, a current ratio of 1.99 and a debt-to-equity ratio of 0.44. The company has a market cap of C$332.68 million, a P/E ratio of 9.92 and a beta of 1.29.
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last announced its earnings results on Thursday, November 12th. The company reported C$0.60 earnings per share for the quarter. The company had revenue of C$18.08 million for the quarter. Cipher Pharmaceuticals had a return on equity of 25.48% and a net margin of 69.98%. On average, analysts forecast that Cipher Pharmaceuticals Inc. will post 1.29 earnings per share for the current year.
Insider Buying and Selling
In other news, Director Craig Mull acquired 20,000 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were purchased at an average cost of C$14.16 per share, with a total value of C$283,200.00. Following the acquisition, the director directly owned 1,009,953 shares in the company, valued at C$14,300,934.48. This represents a 2.02% increase in their position. 42.00% of the stock is currently owned by corporate insiders.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.
Further Reading
- Five stocks we like better than Cipher Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
